Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, announced that it has signed agreements with six additional health plans across 10 states bringing the Company’s total national contracted membership to more than 174 million lives. Response Genetics, Inc. (NASDAQ:RGDX) shares after opening at $1.35 moved to $1.56 on last trade day and at the end of the day closed at $1.42. Company price to sales ratio in past twelve months was calculated as 2.68 and price to cash ratio as 11.94. Response Genetics, Inc. (NASDAQ:RGDX) showed a positive weekly performance of 26.79%.
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced the pricing of its previously announced underwritten public offering of 11,325,000 shares of its common stock at an offering price of $2.21 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,698,750 shares of common stock to cover over-allotments, if any. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares advanced 8.60% in last trading session and ended the day on $2.40. CPRX return on equity ratio is recorded as -73.10% and its return on assets is -59.70%. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) yearly performance is 433.33%.
eRAD, a division of RadNet, Inc. (Nasdaq:RDNT), an industry leader in Web-based RIS, PACS and Teleradiology workflow solutions, announced the company has taken more than fourteen orders from new customers during the first quarter of 2014. eRAD’s products and services are available from a number of geographically dispersed valued-added resellers, brokers, and/or distributors in the United States and abroad, as well as direct from the manufacturer. eRAD’s Authorized Resellers Listing. RadNet Inc. (NASDAQ:RDNT) shares moved up 5.28% in last trading session and was closed at $3.39, while trading in range of $3.19-$3.46. RadNet Inc. (NASDAQ:RDNT) year to date performance is 102.99%.
Magellan Petroleum Corporation (NASDAQ:MPET) announced that on March 31, 2014 (the “Completion Date”), the Company completed the transaction contemplated by the Share Sale and Purchase Deed (the “Sale Deed”) entered into with Central Petroleum Limited (“Central”) (ASX: CTP), a Brisbane, Australia based junior exploration and production company that operates one of the largest holdings of prospective onshore acreage in Australia. The Company and Central had previously entered into the Sale Deed on February 17, 2014 (the “Execution Date”). Magellan Petroleum Corporation (NASDAQ:MPET) weekly performance is 13.57%. On last trading day company shares ended up $1.59. Magellan Petroleum Corporation (NASDAQ:MPET) distance from 50-day simple moving average is 23.62%. Analysts mean target price for the company is $2.40.